Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human Clinical Study With RNA-Immunotherapy Combination of IVAC_W_bre1_uID and IVAC_M_uID for Individualized Tumor Therapy in Triple Negative Breast Cancer Patients

NCT02316457 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT02316457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02316457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human Clinical Study With RNA-Immunotherapy Combination of IVAC_W_bre1_uID and IVAC_M_uID for Individualized Tumor Therapy in Triple Negative Breast Cancer Patients
Lead sponsor
BioNTech SE
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2016
Completion date
May 17, 2023
Enrollment
42 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer (triple negative breast cancer (tnbc))